CASI Pharmaceuticals (FRA:ENM) Cyclically Adjusted PS Ratio: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ENM CASI Pharmaceuticals Inc FRA:ENM
24 GF Score
Price €1.54
GF Value €13.03
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CASI Pharmaceuticals  (FRA:ENM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


CASI Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


CASI Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Cyclically Adjusted PS Ratio Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.34 1.04 3.83 1.47 0.43

CASI Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 0.58 0.83 0.43 0.00

FRA:ENM vs CMND, VBIO, BIXT: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


FRA:ENM
24GF Score
CASI Pharmaceuticals Inc FRA:ENM
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

CASI Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, CASI Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/116.0564*116.0564
=0.000

Current CPI (Jun. 2026) = 116.0564.

CASI Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 101.400 0.000
201609 0.000 102.400 0.000
201612 0.000 102.600 0.000
201703 0.000 103.200 0.000
201706 0.000 103.100 0.000
201709 0.000 104.100 0.000
201712 0.000 104.500 0.000
201803 0.000 105.300 0.000
201806 0.000 104.900 0.000
201809 0.000 106.600 0.000
201812 0.000 106.500 0.000
201903 0.000 107.700 0.000
201906 0.000 107.700 0.000
201909 0.264 109.800 0.279
201912 0.125 111.200 0.130
202003 0.312 112.300 0.322
202006 0.235 110.400 0.247
202009 0.305 111.700 0.317
202012 0.320 111.500 0.333
202103 0.386 112.662 0.398
202106 0.425 111.769 0.441
202109 0.493 112.215 0.510
202112 0.580 113.108 0.595
202203 0.596 114.335 0.605
202206 0.596 114.558 0.604
202209 0.758 115.339 0.763
202212 1.060 115.116 1.069
202303 0.584 115.116 0.589
202306 0.679 114.558 0.688
202309 0.619 115.339 0.623
202312 0.471 114.781 0.476
202403 0.234 115.227 0.236
202406 0.273 114.781 0.276
202409 0.459 115.785 0.460
202412 0.666 114.893 0.673
202503 0.373 115.116 0.376
202506 0.233 114.907 0.235
202509 0.163 115.471 0.164
202512 0.228 115.832 0.228
202606 0.000 116.056 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 88.2% below its estimated GF Value™ of €13.03.

Key valuation signals for FRA:ENM:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €13.03 vs. price of €1.54 (88.2% below fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CASI Pharmaceuticals Business Description

Other Exchanges CASIF:USA
Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
24GF Score

Get the complete analysis for FRA:ENM

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price
€13.03
GF Value